HMGB1 neutralizing antibody attenuates cardiac injury and apoptosis induced by hemorrhagic shock/resuscitation in rats

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 8, 2015, Pages 1150-1160

  Zhou, Yu ^a   Li, Yan ^b   Mu, Tong ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c Emergency Department   (China)

Author keywords

Anti HMGB1 monoclonal antibody; Apoptosis; Hemorrhagic shock; High mobility group box 1 (HMGB1); Inflammation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADVANCED GLYCATION END PRODUCT; CASPASE 3; CREATINE KINASE MB; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; HEART ENZYME; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY; TLR4 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HEART; HEART FUNCTION; HEART INJURY; HEMORRHAGIC SHOCK; NONHUMAN; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; RESUSCITATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIAC MUSCLE; DRUG EFFECTS; HEART DISEASES; INFLAMMATION; METABOLISM; MOUSE; PATHOLOGY; RAW 264.7 CELL LINE; SHOCK, HEMORRHAGIC; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; HEART DISEASES; HMGB1 PROTEIN; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MYOCARDIUM; RATS, SPRAGUE-DAWLEY; RAW 264.7 CELLS; REPERFUSION INJURY; RESUSCITATION; SHOCK, HEMORRHAGIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940932688     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b15-00026     Document Type: Article

References (27)

1. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science, 285, 248-251 (1999).
2. Lee CH, Yoon SJ, Lee SM. Chlorogenic acid attenuates high mobility group box 1 (HMGB1) and enhances host defense mechanisms in murine sepsis. Mol. Med., 18, 1437-1448 (2013).
3. Cai B, Deitch EA, Ulloa L. Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm., 2010, 642462 (2010).
4. Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, Nagel D, Holdenrieder S. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol., 34, 81-90 (2013).
5. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, Strassheim D, Pitts TM, Tracey KJ, Abraham E. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am. J. Physiol. Cell Physiol., 284, C870-C879 (2003).
6. Tang D, Kang R, Zeh HR 3rd, Lotze MT. High-mobility group box 1 and cancer. Biochim. Biophys. Acta, 1799, 131-140 (2010).
7. Zhao H, Perez JS, Lu K, George AJ, Ma D. Role of Toll-like receptor-4 in renal graft ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol., 306, F801-F811 (2014).
8. Li XQ, Lv HW, Tan WF, Fang B, Wang H, Ma H. Role of the TLR4 pathway in blood-spinal cord barrier dysfunction during the bimodal stage after ischemia/reperfusion injury in rats. J. Neuroinflammation, 11, 62 (2014).
9. McGhan LJ, Jaroszewski DE. The role of Toll-like receptor-4 in the development of multi-organ failure following traumatic haemorrhagic shock and resuscitation. Injury, 43, 129-136 (2012).
10. Subeq YM, Peng TC, Hsu BG, Yang FL, Lee R P. Fluid resuscitation therapy application and nursing following hemorrhagic shock. Hu Li Za Zhi, 57, 17-21 (2010).
11. Angele MK, Schneider CP, Chaudry IH. Bench-to-bedside review: Latest results in hemorrhagic shock. Crit. Care, 12, 218 (2008).
12. Yang R, Harada T, Mollen KP, Prince JM, Levy RM, Englert JA, Gallowitsch-Puerta M, Yang L, Yang H, Tracey KJ, Harbrecht BG, Billiar TR, Fink M P. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol. Med., 12, 105-114 (2006).
13. Oozawa S, Mori S, Kanke T, Takahashi H, Liu K, Tomono Y, Asanuma M, Miyazaki I, Nishibori M, Sano S. Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ. J., 72, 1178-1184 (2008).
14. Li J, Gong Q, Zhong S, Wang L, Guo H, Xiang Y, Ichim TE, Wang CY, Chen S, Gong F, Chen G. Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischaemia-reperfusion injury. Nephrol. Dial. Transplant., 26, 469-478 (2011).
15. Naglova H, Bucova M. HMGB1 and its physiological and pathological roles. Bratisl. Lek Listy, 113, 163-171 (2012).
16. Yang QW, Xiang J, Zhou Y, Zhong Q, Li JC. Targeting HMGB1/TLR4 signaling as a novel approach to treatment of cerebral ischemia. Front. Biosci., 2, 1081-1091 (2010).
17. Vande Walle L, Kanneganti TD, Lamkanfi M. HMGB1 release by inflammasomes. Virulence, 2, 162-165 (2011).
18. Tsung A, Tohme S, Billiar TR. High-mobility group box-1 in sterile inflammation. J. Intern. Med., 276, 425-443 (2014).
19. Okuma Y, Liu K, Wake H, Zhang J, Maruo T, Date I, Yoshino T, Ohtsuka A, Otani N, Tomura S, Shima K, Yamamoto Y, Yamamoto H, Takahashi HK, Mori S, Nishibori M. Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann. Neurol., 72, 373-384 (2012).
20. Tong H, Tang Y, Chen Y, Yuan F, Liu Z, Peng N, Tang L, Su L. HMGB1 activity inhibition alleviating liver injury in heatstroke. J Trauma Acute Care Surg., 74, 801-807 (2013).
21. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66, 233-243 (1991).
22. Brint E, O'Callaghan G, Houston A. Life in the Fas lane: Differential outcomes of Fas signaling. Cell. Mol. Life Sci., 70, 4085-4099 (2013).
23. Ehrenschwender M, Wajant H. The role of FasL and Fas in health and disease. Adv. Exp. Med. Biol., 647, 64-93 (2009).
24. Yu WR, Fehlings MG. Fas/FasL-mediated apoptosis and inflammation are key features of acute human spinal cord injury: Implications for translational, clinical application. Acta Neuropathol., 122, 747-761 (2011).
25. Weckbach S, Hohmann C, Denk S, Kellermann P, Huber-Lang MS, Baumann B, Wirth T, Gebhard F, Bachem M, Perl M. Apoptotic and inflammatory signaling via Fas and tumor necrosis factor receptor I contribute to the development of chest trauma-induced septic acute lung injury. J. Trauma Acute Care Surg., 74, 792-800 (2013).
26. Niu FN, Zhang X, Hu XM, Chen J, Chang LL, Li JW, Liu Z, Cao W, Xu Y. Targeted mutation of Fas ligand gene attenuates brain inflammation in experimental stroke. Brain Behav. Immun., 26, 61-71 (2012).
27. Sawant DA, Tharakan B, Tobin RP, Stagg HW, Hunter FA, Newell MK, Smythe WR, Childs EW. Inhibition of Fas-Fas ligand interaction attenuates microvascular hyperpermeability following hemorrhagic shock. Shock, 39, 161-167 (2013).